Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
OCTAPHARMA USA, INC. et al v. BECERRA et al
Case Number:
1:22-cv-02782
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 08, 2024
FDA Settles Allegations Of Uneven Blood Treatment Standards
The U.S. Food and Drug Administration has settled a pharmaceutical company's lawsuit in D.C. federal court accusing the agency of subjecting the company's blood-clotting medication to costly clinical trials and higher standards than its competitors' products were required to meet.
-
September 14, 2022
Pharma Co. Challenges FDA's 'Uneven' Blood Drug Standards
The maker of blood treatment Fibryga hit the U.S. Food and Drug Administration with a suit on Wednesday in D.C. federal court over what it says are the agency's "sharply uneven" standards for blood medications, arguing it was subjected to multimillion-dollar clinical trials while competitors were allowed to skip the "critical step."